Key Highlights
- Loss per share was USD 0.25 against an estimate of a USD 0.28 loss.
- Net loss was USD 51.22 million, against USD 54.92 million a year earlier.
- Research and development expenses decreased by USD 8.3 million, or 17%.
- Cash and cash equivalents were USD 102.39 million at September 30.
Annexon (NASDAQ:ANNX) reported a third quarter 2026 loss per share of USD 0.25, against an estimate of a USD 0.28 loss and a USD 0.37 loss in the third quarter of 2025. Net loss was USD 51.22 million, compared with USD 54.92 million in the prior-year quarter.
The loss from operations was USD 52.24 million, against USD 57.02 million a year earlier. Total operating expenses were USD 52.24 million, against USD 57.02 million, a decrease of USD 4.78 million, or 8%.
Operating Expenses
Research and development expenses decreased by USD 8.3 million, or 17%, compared with the same period in 2025. General and administrative expenses increased by USD 3.6 million, or 49%, primarily driven by a USD 2.0 million increase in consulting and professional services costs for corporate affairs activities supporting late-stage tanruprubart and vonaprument programs.
Interest expense was USD 0.83 million, with none in the prior-year quarter. Interest and other income, net, decreased by USD 0.2 million, or 12%.
Nine-Month Results
For the nine months ended September 30, 2026, net loss was USD 150.71 million, compared with USD 158.43 million in the same period of 2025, and loss per share was USD 0.75, compared with USD 1.08. Total operating expenses for the period were USD 155.52 million, against USD 166.15 million.
Both the loss from operations and total operating expenses for the nine months were USD 155.52 million, against USD 166.15 million.
Cash, cash equivalents and restricted cash were USD 103.42 million at September 30, 2026, compared with USD 163.08 million at December 31, 2025, with restricted cash of USD 1.03 million in both periods. Cash and cash equivalents were USD 102.39 million, compared with USD 162.05 million at the prior Balance Sheet date, and short-term investments were USD 110.99 million, compared with USD 76.29 million.
Clinical Programs
The filing states there are currently no therapies approved by the FDA for Guillain-Barre syndrome and no substantial evidence of effectiveness from the current standard of care. In the placebo-controlled Phase 3 trial of tanruprubart, approximately 90% of treated patients improved by week 1, and more than twice as many treated patients achieved a normal state of health at week 26.
The filing says functional outcomes, complete target engagement and a generally well-tolerated safety profile were observed in the FORWARD study, consistent with Phase 3 and real-world evidence studies. It also notes there are no approved therapies for geographic atrophy targeting the preservation of vision.
Annexon Q3 2026 Earnings: Key Takeaways
Annexon reported a third quarter 2026 loss per share of USD 0.25 and a net loss of USD 51.22 million. Total operating expenses were USD 52.24 million, cash and cash equivalents were USD 102.39 million, and short-term investments were USD 110.99 million.






Please wait processing your request...